Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Get the latest updates from Roche Media News directly as they happen.
Follow now 329 followers
Last updated 10 days ago
10 days ago
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced...
13 days ago
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
14 days ago
MAJESTY, the first global phase III study in primary membranous nephropathy, met...
22 days ago
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met...
about 1 month ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
about 1 month ago
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight...
2 months ago
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...
3 months ago
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...
3 months ago
Giredestrant is the only oral SERD to show superior invasive disease-free survival...
3 months ago
The new PCR test aids in the diagnosis of infectious causes of...
3 months ago
Approval based on phase II NOBILITY and phase III REGENCY studies showing...
3 months ago
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed...